Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31125246 | 1.00 | CHRNB4 (0.42) | CHRNB4CHRNA3MEN1KMT2AMAPT | |
| SCHEMBL7630743 | 0.87 | CHRNB4 (0.43) | CHRNB4CHRNA3MEN1KMT2AMAPT | |
| SCHEMBL31413307 | 0.83 | CHRNB4 (0.45) | CHRNB4CHRNA3MEN1KMT2AMAPT | |
| SCHEMBL10174909 | 0.83 | CHRNB4 (0.45) | CHRNB4CHRNA3MEN1KMT2AMAPT | |
| SCHEMBL19950442 | 0.81 | HSPB1 (0.41) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL29739327 | 0.81 | HSPB1 (0.41) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL16957929 | 0.79 | TSHR (0.57) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL19434621 | 0.79 | MEN1 (0.43) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL16957926 | 0.79 | MEN1 (0.39) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL26633332 | 0.79 | ALDH1A1 (0.42) | MEN1KMT2AMAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4518974-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023239941-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239941-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-3440073-B1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LTD (GB) | 2022-06-08 | — | — | EP | disclosed |
| CN-109071505-B | Kinase inhibitors | 奥苏拉收购有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-10442828-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| EP-3440073-A1 | KINASE INHIBITORS | Topivert Pharma Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-20180305383-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-10-25 | — | — | US | disclosed |
| US-10072034-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-09-11 | — | — | US | disclosed |
| US-20170291917-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-8859548-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| EP-2470528-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-8563553-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072034-B2 | Kinase inhibitors | SYK, LYN, BTK | CHRNB4 2119/4885CHRNA3 2857/4885MEN1 4644/4885 |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | CHRNB4 4524/4885CHRNA3 4639/4885MEN1 1297/4885 |
| US-20180305383-A1 | KINASE INHIBITORS | SYK, LTK, LTB4R | CHRNB4 2204/4885CHRNA3 2824/4885MEN1 4447/4885 |
| US-10442828-B2 | Kinase inhibitors | SYK, LTK, LTB4R | CHRNB4 2204/4885CHRNA3 2824/4885MEN1 4447/4885 |
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | RIPK2, RIPK1, RIPK4 | CHRNB4 4503/4885CHRNA3 3917/4885MEN1 2543/4885 |
| US-20170291917-A1 | KINASE INHIBITORS | SYK, LYN, BTK | CHRNB4 2119/4885CHRNA3 2857/4885MEN1 4644/4885 |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | CHRNB4 4524/4885CHRNA3 4639/4885MEN1 1297/4885 |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | CHRNB4 4524/4885CHRNA3 4639/4885MEN1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.